Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tomaralimab - Neuramedy

Next Previous
Drug Profile

Tomaralimab - Neuramedy

Alternative Names: Anti-TLR2 monoclonal antibody - Opsona Therapeutics; Anti-Toll-like receptor 2 monoclonal antibody - Opsona Therapeutics; NM-101; NM-102- Neuramedy; NM-103; OPN 305

Latest Information Update: 28 Sep 2023

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Opsona Therapeutics
  • Developer Neuramedy; Opsona Therapeutics
  • Class Anti-inflammatories; Antidementias; Antineoplastics; Antiparkinsonians; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Toll-like receptor 2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Delayed graft function; Myelodysplastic syndromes
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Myelodysplastic syndromes
  • Preclinical Alzheimer's disease; CNS disorders; Parkinson's disease
  • Discontinued Delayed graft function

Most Recent Events

  • 28 Sep 2023 No recent reports of development identified for preclinical development in Cancer in Ireland (Parenteral)
  • 10 Apr 2023 Preclinical trials in CNS disorders in South Korea (Parenteral) before April 2023 (Neuramedy pipeline, April 2023)
  • 30 Mar 2023 Neuramedy and Quotient Sciences plan a phase I trial for Parkinson's disease (In volunteers) in United Kingdom (NCT05790382)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top